Agonists, antagonists, and inhibitors used in this investigation
| Compound . | Action . | Reference . |
|---|---|---|
| Tamoxifen (TMX) | Estrogen receptor antagonist | 6 |
| ICI182780 | Nuclear estrogen receptor antagonist | 6 |
| HU-210 | Synthetic CB1 receptor agonist | 32 |
| SR141716 | CB1 receptor antagonist | 32 |
| SR144528 | CB2 receptor antagonist | 32 |
| Cannabidiol (CBD) | Endothelial-type CB receptor antagonist | 33 |
| Abnormal-CBD | Synthetic endothelial-type CB receptor agonist | 33 |
| Capsazepine (CAPS) | Vanilloid receptor antagonist | 11 |
| Capsaicin | Natural vanilloid receptor agonist | 11 |
| l-NAME | NOS inhibitor | 24 |
| AM404 | AMT inhibitor | 34 |
| Suramin | PLD inhibitor | 35 |
| ST638 | Tyrosine kinase/PLD inhibitor | 36 |
| ATFMK | FAAH inhibitor | 20 |
| ETYA | 15-LOX inhibitor | 30 |
| Compound . | Action . | Reference . |
|---|---|---|
| Tamoxifen (TMX) | Estrogen receptor antagonist | 6 |
| ICI182780 | Nuclear estrogen receptor antagonist | 6 |
| HU-210 | Synthetic CB1 receptor agonist | 32 |
| SR141716 | CB1 receptor antagonist | 32 |
| SR144528 | CB2 receptor antagonist | 32 |
| Cannabidiol (CBD) | Endothelial-type CB receptor antagonist | 33 |
| Abnormal-CBD | Synthetic endothelial-type CB receptor agonist | 33 |
| Capsazepine (CAPS) | Vanilloid receptor antagonist | 11 |
| Capsaicin | Natural vanilloid receptor agonist | 11 |
| l-NAME | NOS inhibitor | 24 |
| AM404 | AMT inhibitor | 34 |
| Suramin | PLD inhibitor | 35 |
| ST638 | Tyrosine kinase/PLD inhibitor | 36 |
| ATFMK | FAAH inhibitor | 20 |
| ETYA | 15-LOX inhibitor | 30 |